Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Cost of Revenue: 2021-2024

Historic Cost of Revenue for Tg Therapeutics (TGTX) over the last 4 years, with Dec 2024 value amounting to $38.5 million.

  • Tg Therapeutics' Cost of Revenue rose 200.75% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.0 million, marking a year-over-year increase of 152.01%. This contributed to the annual value of $38.5 million for FY2024, which is 172.35% up from last year.
  • Latest data reveals that Tg Therapeutics reported Cost of Revenue of $38.5 million as of FY2024, which was up 172.35% from $14.1 million recorded in FY2023.
  • Tg Therapeutics' 5-year Cost of Revenue high stood at $38.5 million for FY2024, and its period low was $265,000 during FY2022.
  • Over the past 3 years, Tg Therapeutics' median Cost of Revenue value was $14.1 million (recorded in 2023), while the average stood at $17.6 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first tumbled by 66.46% in 2022, then spiked by 5,232.45% in 2023.
  • Yearly analysis of 4 years shows Tg Therapeutics' Cost of Revenue stood at $790,000 in 2021, then plummeted by 66.46% to $265,000 in 2022, then spiked by 5,232.45% to $14.1 million in 2023, then skyrocketed by 172.35% to $38.5 million in 2024.